To assess the in vivo therapeutic efficacy of nor@MSC‐EVs, IMQ‐induced mice were administered with PBS, nor‐NOHA, MSC‐EVs, nor@MSC‐EVs, or anti‐IL17A (a clinically used bioagent for psoriasis therapy) intravenously on day 1, 3, 5[26] (Figure 5A). The gene discussed is IL17A; the disease is psoriasis.